HBV Infection: From Host and Cellular Entry to Viral Persistence
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Microbiology in Human Health and Disease".
Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 129
Special Issue Editors
Interests: Viral hepatitis; Hepatitis B virus; HBV cellular entry; reporter viruses; CRISPR/Cas editing; reporter proteins; molecular cloning strategies
Interests: viral hepatitis; Hepatitis B virus; HBV cellular entry; lipoprotein/lipid transport and metabolism; neutral lipids (e.g., triglycerides and cholesterolesters); hepatotropic viruses
Special Issue Information
Dear Colleagues,
According to the World Health Organization (WHO) estimation of 2019, 296 million people have been chronically infected with the Hepatitis B virus (HBV) and 820 000 deaths per year are either directly attributed to HBV infection or associated diseases. Due to this high medical relevance, the WHO has proclaimed the elimination of viral hepatitis by 2030. However, although important improvements in HBV therapies have been achieved, there is no reliable cure for chronic HBV infection available to date.
This Special Issue aims to focus on the complete HBV infection cycle, beginning with the virus entry into the host, subsequent virus targeting of the liver, towards viral entry into the host cell and, finally, viral persistence, including cccDNA formation and viral genome integration. Here, we call for articles on clinical studies, case reports and research articles focusing on the discovery of new mechanisms and factors which complete our understanding of the many steps still unresolved HBV infection cycle.
Dr. Jochen M. Wettengel
Dr. Knud Esser
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hepatitis b virus (hbv)
- hbv infection
- hbv replication cycle
- hbv attachment and entry
- hbv liver targeting
- hbv host entry
- hbv cellular entry
- hbv cccdna formation
- hbv cccdna persistence
- hbv genome integration
- hbv novel strategies
- hbv cure
